Company / Gross Margin
Insight Molecular Diagnostics Inc. Gross Margin History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
39.3%
FY2025
5-year range
-52.5% / 64.6%
FY2021-FY2025
Trend
+43.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -1.9% to 39.3% over the past 2 years.
Based on SEC 10-K filings.
39.3% in FY2025 with a 3-year CAGR of -25.3%.
Improved from -1.9% to 39.3% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -25.3pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, gross margin increased 43.2% year-over-year.
- Peak gross margin was recorded in FY2022.
- Lowest gross margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -7.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 39.3% | +43.2% |
| FY2024 | 27.5% | +1561.7% |
| FY2023 | -1.9% | -102.9% |
| FY2022 | 64.6% | +222.9% |
| FY2021 | -52.5% | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026